louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05020405: The Effect of Simvastatin With Guided Bone Regeneration in Ridge Splitting and Simultaneously Implantation
Official title: The Effect of Simvastatin With Guided Bone Regeneration on Ridge Volume in Ridge Splitting and Simultaneously Implantation: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ridge Splitting
Simvastatin
Immediate Implant
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2021-08-25
Enrollment: 22
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Ridge split augmentation technique, with immediate implant placement, reduces the time of the treatment and the time of the final prosthetic reconstruction. Furthermore, compression of the bone increases its density. SMV is also found to promote osteogenic differentiation of bone marrow stem cells, suppress osteoclastic differentiation in bone tissue, and promotes osseointegration around implants in animal studies. The aim of this study is to compare surgical outcomes of the application of the alveolar ridge splitting (ARS) in combination with guided bone regeneration (GBR) using bone grafting and a barrier membrane, associated with immediate implant placement versus ARS in combination with the use of SMV with GBR using bone grafting and a barrier membrane, associated with immediate implant placement in patients with horizontally atrophic jaw bones.


Eligibility criteria: Inclusion Criteria:

* good general health at the time of surgery.
* at least 3 months of healing after tooth extraction.
* horizontally compromised alveolar ridges at least 10 mm high and 3 mm wide.

Exclusion Criteria:

* a vertical bone defect in the edentulous ridge.
* thick cortex in the labial/buccal with less cancellous bone inside
* obvious undercut on the labial/buccal side.
* uncontrolled periodontal conditions or other oral disorders.
* history of radiotherapy in the head and neck region.
* uncontrolled diabetes mellitus or other systematic disorders.
* smokers.
* Pregnancy.
* non-compliant patients.
* allergic reaction to the medications used.

Primary outcomes:
measure: Measurements of the amount of bone formation in millimeters around immediately placed dental implants
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kafr Ash Shaykh
country: Egypt
facility: Faculty of Dentistry, Kafrelsheikh University
Study officials:
affiliation: Kafrelsheikh University
name: Dalia R Issa, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03538405: Short-term Effect of Positioning Cushions and Harmonic Techniques on Paratonia in Persons With Dementia
Official title: Short-term Effect of Positioning Cushions and Harmonic Techniques on Paratonia in Persons With Dementia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dementia
Paratonia
Keywords: harmonic techniques
supporting cushions
intervention
Lead sponsor: University Ghent
Sponsor class: OTHER
First posted: 2018-05-29
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study investigated the short-term effect of both harmonic techniques and supporting cushions on muscle tone, range of motion, pain and daily care activities in 22 patients with moderate to severe paratonia. The study consisted of two parts, each part was conducted during one week. In the first part of the study the short-term effect of supporting cushions was examined; in the second part of the study the additional short-term effect of harmonic techniques was investigated.


Eligibility criteria: Inclusion Criteria:

* dementia (confirmed in medical file)
* presence of moderate to severe paratonia (confirmed with PAI and MAS)
* proxy consent

Exclusion Criteria:

-

Primary outcomes:
measure: Change in muscle tone of biceps brachii and rectus femoris
timeFrame: On each measurement moment (3 or 4 times a day, 3 different days, 2 weeks for each participant)
measure: Change in maximal extension of elbow and knee
timeFrame: On each measurement moment (3 or 4 times a day, 3 different days, 2 weeks for each participant)
measure: Change in pain
timeFrame: On each measurement moment (3 or 4 times a day, 3 different days, 2 weeks for each participant)
measure: Comparison of pain during morning care
timeFrame: rated after morning care, daily during 2 weeks for each participant (control week and intervention week)
measure: Comparison of comfort during morning care
timeFrame: rated after morning care, daily during 2 weeks for each participant (control week and intervention week)
Secondary outcomes:
Other outcomes:
measure: diagnosis of paratonia
timeFrame: for inclusion
measure: paratonia severity
timeFrame: for inclusion
Locations:
city: Ghent
country: Belgium
facility: Vakgroep Revaki - Ghent University
Study officials:
References:
Clinical trial NCT01776905: In Vivo Real-time Detection of Circulating Melanoma Cells
Official title: In Vivo Real-time Detection of Circulating Melanoma Cells
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Melanoma
Keywords: Melanoma
Cancer
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2013-01-28
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts.

Brief summary: The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detection limits of currently existing ex vivo methods.

Detailed description: Study Population: Approximately 80 subjects will be consented in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts as follows:

1. Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be Caucasian and five of whom will be African-American. Subjects in cohort #1 will be used to address the calibration goal of Specific Aim #1.
2. Cohort #2 will consist of 30 subjects who have advanced-stage melanoma will be recruited from the Medical Oncology clinic at UAMS, where advanced stages are defined as Stages III or IV. Subjects in cohort #2 will be used to address the validation goal of Specific Aim #2. Approximately half of the 30 advanced-stage subjects will be Stage III and the other half will be Stage IV.
3. Cohort #3 will consist of 30 subjects with early-stage melanoma will be recruited from the Surgical Oncology clinic at UAMS, where early stages are defined as Stages I or II.

Subjects in cohort #3 will be used to address the detection goal of Specific Aim #3. Approximately 10 of the 30 early-stage subjects will be Stage I and approximately 20 will be Stage II.

Eligibility criteria: Inclusion Criteria:

* Age 18 to 80 years
* Histological documented diagnosis of melanoma
* Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)
* Must be able to sit still for 90 minutes

Exclusion Criteria:

* Active infection
* Current and significant medical or surgical condition as determined by the Investigator
* Diagnosis or evidence of organic brain syndrome
* Pregnancy or breastfeeding

Primary outcomes:
measure: Number of participants that possess circulating tumor cells.
timeFrame: 14-21 days
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Jumin Sunde, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02458105: Acceptance & Commitment Therapy for Psychotic Inpatients
Official title: Acceptance & Commitment Therapy for Psychotic Inpatients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Acute Psychosis
Keywords: Acceptance and commitment therapy
Cognitive behavior therapy
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: Stockholm University
First posted: 2015-05-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overarching aim of the research project is to investigate whether Acceptance \& Commitment Therapy (ACT) is an efficacious psychotherapeutic method of treatment for inpatients suffering from acute psychosis.

The method will be applied in two ways. Firstly, as an individual treatment for patients. Secondly, as an integrated part of the daily work on an inpatient ward, administered by nurses and assistant nurses trained in the method.


Eligibility criteria: Inclusion Criteria:

* Admitted to a specified psychiatric inpatient ward during the time-period of the study; psychotic spectrum diagnosis as specified in patient charts; assessed by contact person on the ward as having delusions or hallucinations.

Exclusion Criteria:

* Cognitive difficulties to an extent where informed consent cannot be given.

Primary outcomes:
measure: Rehospitalization
timeFrame: 12 months
Secondary outcomes:
measure: Bull's Eye Values Inventory
timeFrame: 12 months
measure: EQ-5D
timeFrame: 12 months
measure: Clinical Global Impression Scale
timeFrame: 12 months
measure: Acceptance & Action Questionnaire
timeFrame: 12 months
measure: Psychotic Symptom Rating Scales
timeFrame: 12 months
measure: Checklist of Unit Behaviors
timeFrame: During inpatient care.
Other outcomes:
Locations:
city: Västerås
country: Sweden
facility: Västmanland Hospital, Västerås, Västmanland County Council
Study officials:
affiliation: Stockholm University; Karolinska Institutet, department of Clinical Neuroscience & Centre for Psychiatry Research and Education, Stockholm County Council
name: Tobias Lundgren, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05514405: Effect of Remimazolam and Propofol on Postoperative Delirium
Official title: Effect of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Hip and Knee Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hip Fractures
Knee Osteoarthritis
Femur Fracture
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2022-08-24
Enrollment: 82
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.


Eligibility criteria: Inclusion Criteria:

* elderly patients undergoing hip or knee arthroplasty under general anesthesia.
* body mass index \>30 kg/m2

Exclusion Criteria:

* moderate to severe liver dysfunction
* moderate to severe renal dysfunction
* unable to extubate in the operation room after operation
* benzodiazepine dependence
* sensitivity to anesthetic drugs used for study (Benzodiazepines, Propofol, Remifentanil, Fentanyl citrate, Rocuronium bromide, Sugammadex, Flumazenil)
* acute angle glaucoma
* received (benzodiazepine, antianxiety drugs, antidepressant, antipsychotic drugs) within 24 hours.
* acute psychotic depression
* history stroke or cerebrovascular disease

Primary outcomes:
measure: Incidence of delirium 3 days after the end of operation
timeFrame: Upto 3 days after surgery
Secondary outcomes:
measure: quality of recovery (QoR-15) 3 days after the end of the operation
timeFrame: Upto 3 days after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Sanggye Paik hospital
Study officials:
affiliation: Inje University
name: In-Jung Jun, MD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02820805: Dietary Carbohydrate Consumption on Memory Performance and Mood in Children
Official title: The Effect of Dietary Carbohydrate Consumption on Memory Performance and Mood in Normal Weight and Overweight/Obese Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Ability, General
Keywords: children
dietary carbohydrates
solanum tuberosum
cognition
memory
emotions
blood glucose
Lead sponsor: Toronto Metropolitan University
Sponsor class: OTHER
First posted: 2016-07-01
Enrollment: 22
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the effect of carbohydrates on blood glucose levels, subjective appetite, mood, and memory performance in 9 to 14 year old normal weight (NW) and overweight or obese (OW/OB) children.

Detailed description: NW and OW/OB children, 9-14 years of age, will participate in the experiment. The effect of 5 different meals (mashed potatoes, hash browns, French fries, rice, or beans matched by 50g of available carbohydrate) and meal skipping will be examined. On six separate mornings, one of the meals or no meal will be provided in a random order upon their arrival. Blood glucose, subjective appetite, and mood will be measured at baseline, 10, 30, 60, 120, and 180 minutes after meal consumption. Cognitive performance will be measured using an immediate and delayed word recall test, and two to three executive function tasks at 10, 30, 60, 120, and 180 minutes after meal consumption.

Eligibility criteria: Inclusion Criteria:

* be between 9 and 14 years of age
* be healthy, and have been born at term
* be a native English speaker
* not be taking any medications
* not have allergies to potatoes, rice, or beans.
* normal body weight (between the 5th and 85th BMI percentile for age and gender)
* OW/OB (\>85th BMI percentile for age and gender)

Exclusion Criteria:

* Food sensitivities, allergies, or dietary restrictions
* Health, learning, emotional, or behaivoural problems
* Receiving any medications

Primary outcomes:
measure: Cognitive performance
timeFrame: 10, 30, 60, 120, 180 minutes after meal consumption
Secondary outcomes:
measure: Blood glucose response
timeFrame: Baseline, 10, 30, 60, 120, and 180 minutes after meal consumption
measure: Subjective Appetite and Mood
timeFrame: Baseline, 10, 30, 60, 120, and 180 minutes after meal consumption
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: School of Nutrition, Ryerson University
state: Ontario
Study officials:
affiliation: Toronto Metropolitan University
name: Nick Bellissimo, PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00310505: Amphotericin B Treatment in Visceral Leishmaniasis
Official title: Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Visceral Leishmaniasis
Keywords: visceral leishmaniasis
amphotericin B
Kala-azar
Lead sponsor: Banaras Hindu University
Sponsor class: OTHER
First posted: 2006-04-04
Enrollment: 1500
Sex: ALL
Minimum age (years): 2
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.

Detailed description: This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.

Eligibility criteria: Inclusion Criteria:

* Parasitologically proved kala-azar

Exclusion Criteria:

* HIV positive serology

Primary outcomes:
measure: Final cure rate at six months after the end of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Muzaffarpur
country: India
facility: Kala-azar Medical Research Center
state: Bihar
Study officials:
affiliation: Professor of Medicine
name: Shyam Sundar, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007 Sep 1;45(5):556-61. doi: 10.1086/520665. Epub 2007 Jul 23.
Clinical trial NCT05738005: Dietary Reporting in the Amyloidoses
Official title: DRITA Pilot Trial: Dietary Reporting in the Amyloidoses
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Amyloidosis
Lead sponsor: Barbara Ann Karmanos Cancer Institute
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis.

The main question it aims to answer is:

Is it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients

Participants will be asked to:

* Download the MyFitnessPal application on their smartphone and view an online tutorial
* After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal/alternative supplement intake into the MyFitnessPal application on their smartphone.
* complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Diagnosed with any type of amyloidosis
* Speak, read and write in English
* Willing to use the MyFitnessPal app on their own smartphone

Exclusion Criteria:

* a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment
* cognitive or perceptual disturbances

Primary outcomes:
measure: Adherence Rate
timeFrame: 56 days
Secondary outcomes:
measure: Subsequent adherence rate
timeFrame: 63 days (= 56 days + Week 10)
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
Study officials:
affiliation: Barbara Ann Karmanos Cancer Institute
name: Jeffrey Zonder, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05550805: Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)
Official title: Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2022-09-22
Enrollment: 5822
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with coronary artery disease

Brief summary: To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.


Eligibility criteria: Inclusion Criteria:

1. Hospitalized patients with the diagnosis of any type of coronary artery disease;
2. Age ≥18 years of age;
3. Patient or guardian provided informed written consent.

Exclusion Criteria:

1. Prior surgery, trauma or clinically evident coagulopathic bleeding within the previous 2 weeks;
2. Bipass population with missing follow-up records in Qilu Hospital emergency follow-up cohort.

Primary outcomes:
measure: major adverse cardiovascular events
timeFrame: 20191101-20220701
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Yuguo Chen
state: Shandong
Study officials:
References: